Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed chronic lymphocytic leukemia
Journal of Geriatric Oncology (2014)
  • P. Ghia, Vita-Salute San Raffaele University
  • S.E. Coutre, Stanford University
  • R.R. Furman, Cornell University
  • J.P. Sharman, Cancer Institute
  • B.D. Cheson, Georgetown University Medical Center
  • J.M. Pagel, Fred Hutchinson Cancer Research Center
  • P. Hillmen, Leeds Teaching Hospitals NHS Trust
  • J.C. Barrientos, Hofstra University
  • A.D. Zelenetz, Memorial Sloan Kettering Cancer Center
  • T.J. Kipps, University of California, San Diego
  • I.W. Flinn, Sarah Cannon Research Institute
  • H.A. Eradat, University of California, Los Angeles
  • N. Lamanna, Columbia University Medical Center
  • B. Coiffier, University of Lyon
  • A. Pettitt, University of Liverpool
  • X. Li
  • T.M. Jahn, Children's Hospital Los Angeles
  • S.M. O'Brien, University of Texas MD Anderson Cancer Center
  • M.J. Hallek, University of Cologne
Link
Disciplines
Publication Date
January 10, 2014
DOI
10.1016/j.jgo.2014.09.076
Citation Information
P. Ghia, S.E. Coutre, R.R. Furman, J.P. Sharman, et al.. "Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed chronic lymphocytic leukemia" Journal of Geriatric Oncology Vol. 5 (2014)
Available at: http://works.bepress.com/john-pagel/106/